Legal Representation
Attorney
Frances M. Jagla
USPTO Deadlines
Next Deadline
104 days remaining
Statement of Use Due - Extension 3 Granted
Due Date
October 24, 2025
Extension Available
Until October 24, 2024
Application History
26 events| Date | Code | Type | Description |
|---|---|---|---|
| Apr 16, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Apr 15, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Apr 15, 2025 | EXT3 | S | SOU EXTENSION 3 FILED |
| Apr 15, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 11, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Oct 11, 2024 | EXT2 | S | SOU EXTENSION 2 FILED |
| Oct 11, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 11, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 12, 2024 | EXT1 | S | SOU EXTENSION 1 FILED |
| Mar 12, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 12, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Oct 24, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Aug 29, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 29, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Aug 9, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jul 20, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jul 18, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 17, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 17, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jul 3, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jul 3, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jul 3, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jun 25, 2023 | DOCK | D | ASSIGNED TO EXAMINER |
| Mar 23, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Mar 7, 2023 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceuticals for use in the treatment of cancer and blood diseases and disorders; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of metabolic disorders
Class 042
Medical research and medical research information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders; Scientific research, pharmaceutical research, medical research; technical consultation services in the field of research and product development for the treatment of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; scientific consultation services in the fields of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; product development services for others in the fields of immune mediated diseases, inflammatory diseases, oncological disorders and rare diseases; research and development of new products pertaining to the treatment of immune mediated diseases, inflammatory diseases, oncological and rare diseases
First Use Anywhere:
Aug 22, 2006
First Use in Commerce:
Aug 22, 2006
Class 044
Providing healthcare information to healthcare professionals and patients relating to disease states and treatment options; Medical information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"